Alumis’s Envudeucitinib Achieves 68% PASI 90 Response; Q1 Cash $569.5M
Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis showed Week 24 PASI 90 responses of 68.0% and 62.1% and PASI 100 rates of 41.0% and 39.5%. Alumis ended Q1 with $569.5 million cash, a $93.1 million net loss and remains on track for a Q4 2026 NDA submission and Q3 2026 SLE readout.
1. Phase 3 Results Highlight Envudeucitinib Efficacy
Late-breaking Phase 3 ONWARD1 and ONWARD2 data demonstrated early and robust skin clearance in moderate-to-severe plaque psoriasis. By Week 16 patients achieved significant PASI responses, which improved further by Week 24, reaching PASI 90 rates of 68.0% and 62.1% and PASI 100 rates of 41.0% and 39.5%, with an acceptable safety profile.
2. Upcoming Regulatory and Clinical Milestones
Alumis is preparing a New Drug Application submission for envudeucitinib in Q4 2026 following these pivotal Phase 3 results. The company also expects topline data from a potentially pivotal Phase 2b trial in systemic lupus erythematosus in Q3 2026 and continues to evaluate additional immune-mediated indications under its TYK2 franchise strategy.
3. First Quarter 2026 Financial Performance
As of March 31, 2026, Alumis held $569.5 million in cash, cash equivalents and marketable securities, providing runway into late 2027. Collaboration revenue totaled $1.7 million, R&D expenses were $81.5 million, and the company reported a net loss of $93.1 million for the quarter.